Merck
Q4 2022 Earnings Call
Feb 02, 2023, 8:00 a.m. ET
Contents:
- Prepared Remarks
- Questions and Answers
- Call Participants
Prepared Remarks:
Peter Dannenbaum
Thank you, and good morning. Welcome to Merck's fourth-quarter 2022 conference call. Speaking on today's call will be Rob Davis, chairman and chief executive officer; Caroline Litchfield, chief financial officer; and Dean Li, president of Merck Research Labs. Before we get started, I'd like to point out a few items.
You will see that we have items in our GAAP results such as acquisition-related charges, restructuring costs, and certain other items. You should note that we have excluded these from our non-GAAP results and provide a reconciliation in our press release. I would like to remind you that some of the statements that we make today may be considered forward-looking statements within the meaning of the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995.
Such statements are made based on the current beliefs of Merck's management and are subject to significant risks and uncertainties. If our underlying assumptions prove inaccurate or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Our SEC filings, including Item 1A in the 2021 10-K, identify certain risk factors and cautionary statements that could cause the company's actual results to differ materially from those projected in any of our forward-looking statements made this morning. Merck undertakes no obligation to publicly update any forward-looking statements.
During today's call, a slide presentation will accompany our speakers' prepared remarks. The presentation, today's earnings release, as well as our SEC filings are all posted to the Investor Relations section of Merck's website. With that, I'd like to turn the call over to Rob.
Rob Davis -- President
Thanks, Peter. Good morning, and thank you for joining today's call. 2022 was an exceptional year for Merck. Our science-led strategy is working, and I couldn't be more proud of what our team has delivered scientifically, commercially, and operationally.
We're focusing on what matters and keeping the patient at the center of everything we do. We made significant progress in 2022 advancing our broad pipeline with important internal success complemented by a portfolio of strategic acquisitions, collaborations, and partnerships. We have moved the speed and urgency to drive strong progress, and we have provided increased transparency into several of our long-term opportunities, including for GARDASIL, for our cardiovascular pipeline, and more recently, from newer assets that leverage our leadership position in oncology. We enter 2023 with even greater confidence that we're creating a sustainable engine that will bring forth innovation and generate value for both patients and shareholders over the long term.